Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 03:26:20 2024-05-03 pm EDT 5-day change 1st Jan Change
36.66 USD -0.66% Intraday chart for Baxter International Inc. -8.56% -5.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Adjusts Price Target on Baxter International to $40 From $42, Maintains Neutral Rating MT
Evercore ISI Adjusts Price Target on Baxter International to $46 From $50 MT
Jefferies Adjusts Price Target on Baxter International to $43 From $45 MT
Stifel Adjusts Baxter International's Price Target to $44 From $50 MT
Baxter International Q1 Adjusted Earnings, Net Sales Gain; Boosts 2024 Adjusted Profit Guidance MT
Transcript : Baxter International Inc., Q1 2024 Earnings Call, May 02, 2024
(BAX) BAXTER INTERNATIONAL Forecasts Q2 Adjusted EPS Range $0.65 - $0.67 MT
(BAX) BAXTER INTERNATIONAL Sees Fiscal Year 2024 Adjusted EPS Range $2.88 - $2.98 MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Adjusted EPS $0.65 vs. $0.61 Estimate MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B MT
Baxter International Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Edwards Lifesciences Corporation: The story continues Our Logo
Exact Sciences Names Aaron Bloomer CFO MT
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S CI
Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period MT
Citigroup Raises Price Target on Baxter International to $44 From $41, Keeps Neutral Rating MT
Baxter International Receives US FDA Clearance for Novum IQ Large Volume Infusion Pump MT
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy CI
Baxter International Files Definitive Proxy Statement with Securities and Exchange Commission CI
Baxter International Inc. Enters into Fourth Amendment to the Existing $4.0 Billion Term Loan Credit Facility CI
Baxter International Receives a Shareholder Proposal from John Chevedden CI
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data RE
Chart Baxter International Inc.
More charts
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
36.91 USD
Average target price
47.36 USD
Spread / Average Target
+28.30%
Consensus
  1. Stock Market
  2. Equities
  3. BAX Stock
  4. News Baxter International Inc.
  5. TD Cowen Raises Baxter International's Price Target to $50 From $45, Outperform Rating Kept